Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

NCT02847403 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria di Parma as lead sponsor.

NCT NCT02847403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02847403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?
Lead sponsor
Azienda Ospedaliero-Universitaria di Parma
Phase
Phase 3
Overall status
Unknown status
Start date
February 29, 2016
Completion date
October 31, 2021
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive deficit, dysglycemia